Zacks: Analysts Anticipate Supernus Pharmaceuticals Inc (SUPN) to Post $0.44 EPS

Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post earnings of $0.44 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest EPS estimate is $0.49 and the lowest is $0.37. Supernus Pharmaceuticals posted earnings per share of $0.29 during the same quarter last year, which would indicate a positive year over year growth rate of 51.7%. The business is expected to issue its next quarterly earnings results on Monday, November 5th.

On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.96 per share for the current financial year, with EPS estimates ranging from $1.78 to $2.07. For the next fiscal year, analysts expect that the business will post earnings of $2.51 per share, with EPS estimates ranging from $2.07 to $2.85. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The business had revenue of $99.54 million for the quarter, compared to analysts’ expectations of $101.01 million.

Several research firms have recently commented on SUPN. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 31st. Piper Jaffray Companies reissued a “hold” rating and set a $46.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, July 25th. ValuEngine cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Jefferies Financial Group increased their price target on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Stifel Nicolaus increased their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, May 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $54.09.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,795 shares of the firm’s stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $59.92, for a total value of $467,076.40. Following the transaction, the vice president now directly owns 7,795 shares of the company’s stock, valued at $467,076.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Gregory S. Patrick sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the completion of the transaction, the chief financial officer now directly owns 75,975 shares in the company, valued at $4,302,464.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 110,000 shares of company stock worth $6,144,826. Insiders own 6.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in SUPN. Wells Fargo & Company MN boosted its stake in Supernus Pharmaceuticals by 18.6% in the first quarter. Wells Fargo & Company MN now owns 896,110 shares of the specialty pharmaceutical company’s stock valued at $41,041,000 after acquiring an additional 140,688 shares during the last quarter. Rhumbline Advisers boosted its stake in Supernus Pharmaceuticals by 3.6% in the first quarter. Rhumbline Advisers now owns 117,418 shares of the specialty pharmaceutical company’s stock valued at $5,378,000 after acquiring an additional 4,031 shares during the last quarter. Comerica Bank boosted its stake in Supernus Pharmaceuticals by 2.4% in the first quarter. Comerica Bank now owns 54,027 shares of the specialty pharmaceutical company’s stock valued at $2,639,000 after acquiring an additional 1,261 shares during the last quarter. American Century Companies Inc. bought a new position in Supernus Pharmaceuticals in the first quarter valued at approximately $3,620,000. Finally, Prudential Financial Inc. boosted its stake in Supernus Pharmaceuticals by 1.0% in the first quarter. Prudential Financial Inc. now owns 400,578 shares of the specialty pharmaceutical company’s stock valued at $18,346,000 after acquiring an additional 3,833 shares during the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

SUPN opened at $48.05 on Friday. Supernus Pharmaceuticals has a one year low of $33.30 and a one year high of $61.25. The company has a current ratio of 2.74, a quick ratio of 2.54 and a debt-to-equity ratio of 0.82. The company has a market cap of $2.57 billion, a PE ratio of 38.13 and a beta of 0.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply